Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON28651Recruiting
Open-label trial of polyvalent human immunoglobulin in autoimmune epilepsy and Autoimmune Encephalitis (AE), sponsored by Erasmus MC. Primary endpoints: Responder rate by seizure reduction and Seizure freedom. Started Aug 2020; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON28651.